News
APLM
18.60
+1.92%
0.35
Apollomics H1 EPS $(4.06) Up From $(11.37) YoY
Benzinga · 1d ago
Press Release: Apollomics Reports First-Half 2026 Financial Results
Dow Jones · 1d ago
Press Release: Apollomics Reports First-Half 2026 -2-
Dow Jones · 1d ago
Apollomics price target lowered to $38 from $50 at Rodman & Renshaw
TipRanks · 1d ago
Weekly Report: what happened at APLM last week (1102-1106)?
Weekly Report · 1d ago
Apollomics GAAP EPS of -$4.04
Seeking Alpha · 4d ago
Weekly Report: what happened at APLM last week (1026-1030)?
Weekly Report · 11/02 09:10
Weekly Report: what happened at APLM last week (1019-1023)?
Weekly Report · 10/26 09:10
Weekly Report: what happened at APLM last week (1012-1016)?
Weekly Report · 10/19 09:10
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 10/13 17:06
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/12 17:05
Weekly Report: what happened at APLM last week (1005-1009)?
Weekly Report · 10/12 09:10
Weekly Report: what happened at APLM last week (0928-1002)?
Weekly Report · 10/05 09:10
Weekly Report: what happened at APLM last week (0921-0925)?
Weekly Report · 09/28 09:10
Weekly Report: what happened at APLM last week (0914-0918)?
Weekly Report · 09/21 09:10
Weekly Report: what happened at APLM last week (0907-0911)?
Weekly Report · 09/14 09:10
Weekly Report: what happened at APLM last week (0831-0904)?
Weekly Report · 09/07 09:09
Weekly Report: what happened at APLM last week (0824-0828)?
Weekly Report · 08/31 09:10
Weekly Report: what happened at APLM last week (0817-0821)?
Weekly Report · 08/24 09:10
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 08/18 12:06
More
Webull provides a variety of real-time APLM stock news. You can receive the latest news about APOLLOMICS INC through multiple platforms. This information may help you make smarter investment decisions.
About APLM
Apollomics Inc. is a clinical-stage biopharmaceutical company focusing on discovering and developing oncology therapies to address unmet medical needs, especially for difficult-to-treat and treatment-resistant cancers. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate.